Effettuare il login Iscriviti gratis

Acelrx Pharmaceuticals Inc Entrate Q/Q

Cos'è Entrate Q/Q di Acelrx Pharmaceuticals Inc?

Entrate Q/Q di Acelrx Pharmaceuticals Inc è -76.92%

Qual è la definizione di Entrate Q/Q?

La crescita trimestrale dei ricavi, anno su anno , è l'aumento delle entrate di un'azienda rispetto alla performance nel corrispondente trimestre dell'anno precedente espresso in percentuale.

Quaterly revenue growth is the amount by which revenue exceeds the revenue in a previous quarter. It is beneficial to look at a company's quarterly financials to identify how the company is performing over time not just during the current period. The usage of year over year comparison is advantageous in removing seasonalities in reporting the quarterly revenue growth and observing longterm trends.

Entrate Q/Q di aziende nel Health Care settore su NASDAQ rispetto a Acelrx Pharmaceuticals Inc

Cosa fa Acelrx Pharmaceuticals Inc?

acelrx pharmaceuticals inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. the company’s product candidates, dsuvia™ (known as arx-04 outside of the united states) and zalviso®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. dsuvia is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. the phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. in clinical studies, dsuvia demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and v

Aziende con entrate q/q simili a Acelrx Pharmaceuticals Inc